JP2023543472A5 - - Google Patents
Info
- Publication number
- JP2023543472A5 JP2023543472A5 JP2023519744A JP2023519744A JP2023543472A5 JP 2023543472 A5 JP2023543472 A5 JP 2023543472A5 JP 2023519744 A JP2023519744 A JP 2023519744A JP 2023519744 A JP2023519744 A JP 2023519744A JP 2023543472 A5 JP2023543472 A5 JP 2023543472A5
- Authority
- JP
- Japan
- Prior art keywords
- viral vector
- nucleic acid
- acid molecule
- optionally
- envelope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011064132 | 2020-09-30 | ||
| CN202011064132.2 | 2020-09-30 | ||
| PCT/CN2021/121509 WO2022068837A1 (en) | 2020-09-30 | 2021-09-29 | Viral vectors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543472A JP2023543472A (ja) | 2023-10-16 |
| JP2023543472A5 true JP2023543472A5 (cg-RX-API-DMAC7.html) | 2024-09-27 |
Family
ID=80949726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519744A Pending JP2023543472A (ja) | 2020-09-30 | 2021-09-29 | ウイルスベクター及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240076690A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4222269A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023543472A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114317609A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022068837A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116497065A (zh) * | 2022-01-25 | 2023-07-28 | 广东东阳光药业股份有限公司 | 病毒载体及其应用 |
| CN117802163A (zh) * | 2022-09-30 | 2024-04-02 | 深圳市济因生物科技有限公司 | 靶向载体及其制备方法与用途 |
| CN116064622B (zh) * | 2023-02-13 | 2023-10-13 | 优睿赛思(武汉)生物科技有限公司 | Claudin6-mCherry报告基因CHO-K1稳转细胞株制备及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004106360A2 (en) * | 2003-05-23 | 2004-12-09 | Mount Sinai School Of Medicine Of New York University | Viral vectors with improved properties |
| EP1975239A1 (en) * | 2006-09-27 | 2008-10-01 | Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer | Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening |
| EP2476754A1 (en) * | 2011-01-14 | 2012-07-18 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv) |
| JP6412579B2 (ja) * | 2014-01-10 | 2018-10-24 | シリオン・バイオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 偽型レンチウイルスベクター |
| US12365916B2 (en) * | 2017-10-30 | 2025-07-22 | Miltenyi Biotec B.V. & Co. KG | Adapter-based retroviral vector system for the selective transduction of target cells |
| CN107936122A (zh) * | 2017-12-29 | 2018-04-20 | 河南省华隆生物技术有限公司 | 一种慢病毒及其制备方法和应用 |
| WO2019136432A1 (en) * | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| EP3911371A4 (en) * | 2019-01-18 | 2023-04-26 | University of Southern California | METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY |
-
2021
- 2021-09-29 JP JP2023519744A patent/JP2023543472A/ja active Pending
- 2021-09-29 CN CN202111154043.1A patent/CN114317609A/zh active Pending
- 2021-09-29 EP EP21874493.6A patent/EP4222269A4/en active Pending
- 2021-09-29 US US18/028,029 patent/US20240076690A1/en active Pending
- 2021-09-29 WO PCT/CN2021/121509 patent/WO2022068837A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Finke et al. | Dissociation of rabies virus matrix protein functions in regulation of viral RNA synthesis and virus assembly | |
| Tapparel et al. | Inhibition of Sendai virus genome replication due to promoter-increased selectivity: a possible role for the accessory C proteins | |
| Kukkonen et al. | L protein, the RNA-dependent RNA polymerase of hantaviruses | |
| Rueda et al. | Loss of conserved cysteine residues in the attachment (G) glycoprotein of two human respiratory syncytial virus escape mutants that contain multiple AG substitutions (hypermutations) | |
| Robison et al. | The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly | |
| Li et al. | Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles | |
| EP2583974B1 (en) | Pseudotyping of foamy viruses | |
| Radoshitzky et al. | Ebolavirus Δ-peptide immunoadhesins inhibit Marburgvirus and Ebolavirus cell entry | |
| WO2021254341A1 (zh) | 一种冠状病毒假病毒包装系统及其包装方法、冠状病毒假病毒在评估消杀效力中的应用 | |
| Pohl et al. | Measles virus M and F proteins associate with detergent-resistant membrane fractions and promote formation of virus-like particles | |
| Latorre et al. | The various Sendai virus C proteins are not functionally equivalent and exert both positive and negative effects on viral RNA accumulation during the course of infection | |
| WO1997016538A1 (en) | (-)-strand rna virus vector having autonomously replicating activity | |
| Maeda et al. | The intracellular association of the nucleocapsid protein (NP) of hantaan virus (HTNV) with small ubiquitin-like modifier-1 (SUMO-1) conjugating enzyme 9 (Ubc9) | |
| Sarute et al. | Signal-regulatory protein alpha is an anti-viral entry factor targeting viruses using endocytic pathways | |
| Seth et al. | Mutations in the cytoplasmic domain of a paramyxovirus fusion glycoprotein rescue syncytium formation and eliminate the hemagglutinin-neuraminidase protein requirement for membrane fusion | |
| Koga et al. | Actin-modulating protein cofilin is involved in the formation of measles virus ribonucleoprotein complex at the perinuclear region | |
| JP6629210B2 (ja) | エンベロープウイルスの産生方法 | |
| Hui et al. | YRKL sequence of influenza virus M1 functions as the L domain motif and interacts with VPS28 and Cdc42 | |
| Yamayoshi et al. | Mapping of a region of Ebola virus VP40 that is important in the production of virus-like particles | |
| JP2023543472A (ja) | ウイルスベクター及びその使用 | |
| Liu et al. | The effect of the HRB linker of Newcastle disease virus fusion protein on the fusogenic activity | |
| Vincent et al. | Restriction of measles virus RNA synthesis by a mouse host cell line: trans-complementation by polymerase components or a human cellular factor (s) | |
| Li et al. | A novel amino acid position in hemagglutinin glycoprotein of measles virus is responsible for hemadsorption and CD46 binding | |
| Fukuhara et al. | Mutational analysis of the Sendai virus V protein: importance of the conserved residues for Zn binding, virus pathogenesis, and efficient RNA editing | |
| Irie et al. | Significance of the YLDL motif in the M protein and Alix/AIP1 for Sendai virus budding in the context of virus infection |